Rekombinanter NKG2A (Monalizumab Biosimilar) Antikörper
-
- Target Alle NKG2A (Monalizumab Biosimilar) Produkte
- NKG2A (Monalizumab Biosimilar)
- Antikörpertyp
- Recombinant Antibody
- Reaktivität
- Human
-
Wirt
-
Humanized
- Expressionssystem
- Mammalian cells
-
Klonalität
- Monoklonal
-
Konjugat
- Dieser NKG2A (Monalizumab Biosimilar) Antikörper ist unkonjugiert
-
Applikation
- ELISA, Western Blotting (WB)
- Verwendungszweck
- Monalizumab Biosimilar - Anti-KLRC1, NKG2A, CD159a, CD94 mAb - Research Grade
- Produktmerkmale
- Antibody Type: IgG4-kappa
- Aufreinigung
- Recombinant antibody expressed in mammalien cells and purified.
- Reinheit
- > 85%
- Güteklasse
- Research Grade
- Isotyp
- IgG4
-
-
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Buffer
- PBS buffer PH7.5
- Lagerung
- -80 °C
- Informationen zur Lagerung
- store at -80°C
-
- Target
- NKG2A (Monalizumab Biosimilar)
- Abstract
- NKG2A (Monalizumab Biosimilar) Produkte
- Hintergrund
- Monalizumab is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC).
- CAS-Nummer
- 1228763-95-8
-